MVZ im Altstadt-Carree Fulda GmbH
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The General Physician department at MVZ im Altstadt‑Carree Fulda GmbH conducts research aimed at preventing heart attacks, strokes, and heart failure in adults at high cardiovascular risk.
- Prevention of heart failure in high‑risk populations
- Evaluation of novel lipid‑lowering agents
- Assessment of therapies for heart failure with preserved ejection fraction
- Investigation of treatments that reduce major adverse cardiovascular events
- Exploration of combined approaches for obesity‑related cardiac risk
These studies reinforce the site’s dedication to improving cardiovascular health in the community.
Digestive System Diseases
Research in the digestive field targets functional bowel disorders and chronic constipation, seeking safer and more effective symptom relief for patients.
- Oral probiotic therapy for diarrhoea‑predominant irritable bowel syndrome
- Long‑term safety of laxative treatment for chronic constipation
- Impact of gut‑focused interventions on quality of life
- Dietary strategies to manage functional bowel symptoms
The program highlights the clinic’s commitment to advancing digestive health care.
Immune System Diseases
Studies explore the role of inflammation in cardiovascular and metabolic conditions, evaluating agents that modulate the immune response.
- Targeting inflammatory pathways in heart failure
- Anti‑inflammatory therapies for patients with high cardiovascular risk
- Immune modulation strategies in metabolic disease management
This work supports a growing interest in linking immune health to chronic disease outcomes.
Nutritional and Metabolic Diseases
The site focuses on interventions for type 2 diabetes, obesity, and related metabolic disorders, aiming to improve glycaemic control and reduce cardiovascular complications.
- Weight‑loss programs combined with diabetes management
- Comparative effectiveness of weekly versus daily insulin regimens
- New glucose‑lowering agents and their impact on heart health
- Therapies addressing hyperlipidaemia and metabolic syndrome
These initiatives reflect a comprehensive approach to metabolic health in the Fulda region.
Otorhinolaryngologic Diseases
Clinical work includes evaluating symptomatic treatments for acute pharyngitis, aiming to provide rapid relief while ensuring safety.
- Lozenges containing benzydamine for sore throat relief
- Non‑invasive options for managing throat inflammation
- Comparison of active comparators and placebo in pharyngitis symptom control
The research contributes to better outpatient care for common ENT complaints.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1AstraZeneca AB3active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MVZ im Altstadt-Carree Fulda GmbH
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, randomised, double-blind, parallel-group, 76-week, efficacy and safety study of BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity and type 2 diabetes mellitus | Boehringer Ingelheim Espana S.A., Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG | Phase III | Not Recruiting | Jan 2024 | Mar 2026 |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dapagliflozin | 3 | Unknown | 2023-08-02 | 2025-05-06 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.